Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum -Lactamases | Zendy

David L. Paterson | Zendy; WenChien Ko | Zendy; Anne von Gottberg | Zendy; Sunita Mohapatra | Zendy; José María Casellas | Zendy; Herman Goossens | Zendy; Lütfiye Mülazımoğlu | Zendy; Gordon M. Trenholme | Zendy; Keith P. Klugman | Zendy; Robert A. Bonomo | Zendy; Louis B. Rice | Zendy; Marilyn M. Wagener | Zendy; J. G. McCormack | Zendy; Victor L. Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum -Lactamases

Author(s) -

David L. Paterson,

WenChien Ko,

Anne von Gottberg,

Sunita Mohapatra,

José María Casellas,

Herman Goossens,

Lütfiye Mülazımoğlu,

Gordon M. Trenholme,

Keith P. Klugman,

Robert A. Bonomo,

Louis B. Rice,

Marilyn M. Wagener,

J. G. McCormack,

Victor L. Yu

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/420816

Subject(s) - bacteremia , medicine , klebsiella pneumoniae , imipenem , antibiotics , carbapenem , pneumonia , klebsiella pneumonia , intensive care medicine , microbiology and biotechnology , antibiotic resistance , pseudomonas aeruginosa , bacteria , biology , biochemistry , genetics , escherichia coli , gene

The prevalence of extended-spectrum beta -lactamase (ESBL) production by Klebsiella pneumonia approaches 50% in some countries, with particularly high rates in eastern Europe and Latin America. No randomized trials have ever been performed on treatment of bacteremia due to ESBL-producing organisms; existing data comes only from retrospective, single-institution studies. In a prospective study of 455 consecutive episodes of Klebsiella pneumoniae bacteremia in 12 hospitals in 7 countries, 85 episodes were due to an ESBL-producing organism. Failure to use an antibiotic active against ESBL-producing K. pneumoniae was associated with extremely high mortality. Use of a carbapenem (primarily imipenem) was associated with a significantly lower 14-day mortality than was use of other antibiotics active in vitro. Multivariate analysis including other predictors of mortality showed that use of a carbapenem during the 5-day period after onset of bacteremia due to an ESBL-producing organism was independently associated with lower mortality. Antibiotic choice is particularly important in seriously ill patients with infections due to ESBL-producing K. pneumoniae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research